Press

Israel-Based Clearmind Announces Additional Positive Results from the Third Part of its Pre-Clinical Study for Cocaine Addiction Treatment

Jan 18 • 3 min read

Clearmind Medicine Inc. (Nasdaq, CSE: CMND | FSE: CWY), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced additional positive pre-clinical results in its ongoing series of research studies conducted to illuminate the tremendous potential of MEAI and its effect on substance-use-disorder (SUD). The…

FSD Pharma Inc. Board Authorized Share Repurchase Program

Jan 16 • 2 min read

FSD Pharma (NASDAQ: HUGE | CSE: HUGE | FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, has announced a share repurchase program. The company’s board of directors approved the repurchase under a normal course issuer bid; the bid is comprised of…

Mindbloom partners with This is Jane Project to offer affordable at-home ketamine therapy to trauma survivors

Jan 16 • 3 min read

Mindbloom, the world’s largest provider of ketamine therapy, announced Monday the launch of their partnership with This is Jane Project, a nonprofit organization that supports and builds community for women and non-binary survivors of trauma. Through this partnership, This is Jane Project’s members will be able to access Mindbloom’s at-home ketamine therapy programs at a substantial…

atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from Phase 1 Single and Multiple Ascending Dose Trial of GRX-917

Jan 16 • 4 min read

Today, atai Life Sciences N.V. (Nasdaq: ATAI) a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, and its subsidiary GABA Therapeutics, announced final positive results from a Phase 1 clinical trial of GRX-917 that were previously announced as preliminary results during atai’s R&D day. The randomized, double-blind, placebo-controlled trial was designed…

Bright Minds Biosciences Announces Resignation of Board Member

Jan 16 • 2 min read

Bright Minds Biosciences (Nasdaq: DRUG | CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced that Dr. Doug Williamson has resigned from its Board of Directors. Dr. Williamson has accepted a new full-time role that precludes his participation on the Bright Minds…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436